12:00 AM
Jul 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TNFalpha kinoid: Phase IIa ongoing

Neovacs will begin enrollment in a second dose cohort of a double-blind, placebo-controlled Phase IIa trial based on a review of safety data from the first...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >